Testing of the in vivo therapeutic efficacy on the cutaneous herpes simplex infections of the autochthonous product 5% Acyclovir ointment.

The experimental results of the in vivo testing of an autochthonous pharmaceutical Acyclovir form prepared for the topical treatment of herpetic infections with a mucocutaneous location are shown in this paper. This testing on laboratory animals continues the in vivo performed investigations regarding the antiviral activity of this compound, which have proved that the efficacy of the inhibitory action exerted by the product on the Herpes simplex virus multiplication is comparable with the characteristics of the standard substance (Acyclovir-Zovirax Wellcome). By testing the therapeutic efficacy of the autochthonous Acyclovir preparation on an experimental model of cutaneous herpes infection in the newborn rat, it is demonstrated in a statistically significant manner that the product exerts a strong inhibitory action on the virus multiplication at the level of epidermis (proved by the lowering of virus production in the cutaneous tissue); the result is a drastic reduction of local herpes vesicles and of virus propagation in the neuraxis attended by the appearance of herpes meningo-encephalitis with a lethal course. The preparation is well tolerated (phenomena of local intolerance or remote toxicity were not observed). These in vivo positive results corroborated by those obtained in vitro complete the experimental argumentation necessary to support the proposal regarding the clinical trial of the product.